![Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial - The Lancet Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/2000977426/2003577226/gr1.gif)
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial - The Lancet
![Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C | Nature Reviews Gastroenterology & Hepatology Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fnrgastro.2011.21/MediaObjects/41575_2011_Article_BFnrgastro201121_Fig1_HTML.jpg)
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C | Nature Reviews Gastroenterology & Hepatology
![Interferon therapy for COVID-19 and emerging infections: Prospects and concerns | Cleveland Clinic Journal of Medicine Interferon therapy for COVID-19 and emerging infections: Prospects and concerns | Cleveland Clinic Journal of Medicine](https://www.ccjm.org/content/ccjom/early/2020/12/01/ccjm.87a.ccc066/F1.large.jpg)
Interferon therapy for COVID-19 and emerging infections: Prospects and concerns | Cleveland Clinic Journal of Medicine
![Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs - ScienceDirect Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S027869152200206X-ga1.jpg)
Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs - ScienceDirect
![Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection - eBioMedicine Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection - eBioMedicine](https://www.thelancet.com/cms/attachment/9c54bdd3-27e7-4d3a-963f-674a3d1226e1/gr1_lrg.jpg)
Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection - eBioMedicine
![Time of occurrence of interferon-related side effects during the course... | Download Scientific Diagram Time of occurrence of interferon-related side effects during the course... | Download Scientific Diagram](https://www.researchgate.net/publication/246764115/figure/fig1/AS:486165649334272@1492922331071/Time-of-occurrence-of-interferon-related-side-effects-during-the-course-of-treatment.png)
Time of occurrence of interferon-related side effects during the course... | Download Scientific Diagram
![Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides - JDDonline - Journal of Drugs in Dermatology Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides - JDDonline - Journal of Drugs in Dermatology](https://s3.amazonaws.com/dl.jddonline.com/articleimages/20_3_WALKER/Clinical_Trial_of_High_Dose_Pegylated_Interferon_Alfa_2b_Combined_With_Phototherapy_in_Advanced_Stage_Mycosis_Fungoides_Table2.jpg)
Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides - JDDonline - Journal of Drugs in Dermatology
![Interferon and ribavirin for chronic hepatitis C: should it be administered in the new treatment era? Interferon and ribavirin for chronic hepatitis C: should it be administered in the new treatment era?](https://actagastro.org/wp-content/uploads/2017/04/MO-15-051-IMG03.jpeg)
Interferon and ribavirin for chronic hepatitis C: should it be administered in the new treatment era?
![Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial - The Lancet Neurology Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/ec867148-d63b-4965-9a65-14768e2658a6/gr1.gif)